← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBiologicstaleHoffmann-La RochePhase 2

89Zr-Df-IAB22M2C (89Zr-Df-IAB22M2C)

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 10상태 RECRUITING
ADCBiologicstaleAstellas Pharma IncPhase 1

AGS-22M6E (AGS-22M6E)

Tumors; Medical Oncology · Tumors

#Tumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 10상태 ACTIVE
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Combined With Sintilimab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 10상태 ACTIVE
ADCBiologicstaleCuris, Inc.Phase 1

Emavusertib (Emavusertib)

Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 10상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

R-mini-CHOP (R-mini-CHOP)

Large B-cell Lymphoma · DLBCL

#DLBCL#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 94.1%임상시험 10상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 2

Taselisib (Taselisib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 50%임상시험 10상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 1.4%임상시험 10상태 DISCONTINUED
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Amcenestrant (Amcenestrant)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 42.3%임상시험 9상태 RECRUITING
ADCBiologicstaleThe Thai Lymphoma Study GroupPhase 2

B-MAD chemotherapy (B-MAD chemotherapy)

Extranodal NK/T-cell Lymphoma · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 9상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 6%임상시험 9상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 2

CHEP (CHEP)

Lymphoma; Adult T-Cell Leukemia/Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 9상태 RECRUITING
ADCBiologicstaleCSPC ZhongQi Pharmaceutical Tec…Phase 3

DP303c (DP303c)

HER2-positive Breast Cancer · Localized Advanced or Metastatic Gastric

#LocalizedAdvancedorMetastaticGas#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 9상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Lasofoxifene (Lasofoxifene)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 9상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

R-DXd (R-DXd)

Solid Cancer · Solid Cancer

#SolidCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd))

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 RECRUITING
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab Vedotin, Rituximab (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab vedotin and Rituximab (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleCelldex TherapeuticsPreclinical

glembatumumab vedotin (glembatumumab vedotin)

Metastatic gpNMB Expressing Triple Negative Breast Cancer · Melanoma

#Melanoma#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 21%임상시험 9상태 ACTIVE
ADCBiologicstaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, 6 cycle RC48 and JS001)

Urology · Urology

#Urology#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 8상태 RECRUITING
ADCBiologicstaleAbbViePhase 2

ABT-414 (ABT-414)

Malignant Glioma; Glioblastoma Multiforme · Malignant Glioma

#MalignantGlioma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 14.3%임상시험 8상태 ACTIVE

24 / 54 페이지

← 이전다음 →